Page 137 - Read Online
P. 137

Page 18 of 21                                                        Carr et al. Vessel Plus 2020;4:12  I  http://dx.doi.org/10.20517/2574-1209.2020.01

               minor differences in the pre-CABG patients’ risk factor frequency (which may have been associated with
               provider-based off-pump patient selection criteria), the pre-CABG patient risk factors identified were
               extremely similar to the overall findings, as reported above. Given the smaller number of on-pump vs.
               off-pump CABG mortality risk model comparisons reported, however, these findings may have limited
               generalizability.


               When reviewing the frequency distribution of preoperative model risk variables, it is striking how very
               few modifiable (as opposed to non-modifiable) patient risk factors have been identified with a post-CABG
               mortality impact. As an inherently non-modifiable risk factor, the risk for post-CABG mortality increases
               as a patient’s age increases. Perhaps by the time a patient is being evaluated for a CABG procedure, the
               negative prognostic impact for the most common preoperative risk factors, such as diabetes mellitus
               and poor left ventricular ejection fraction, may be difficult to reverse or otherwise counteract in the ST;
               however, these impacts can be seen in LT models.

               In contrast, several of these reported patient risk factors have potential to be mitigated. As an example,
               body mass index or another marker of body habitus (e.g., height, weight, or body surface area) was
               included in 31/133 (23%) of ST models considering only preoperative risk factors. Similarly, a measure of
               smoking or tobacco use was considered in only 4/133 (3%). Although it is a well-known fact that these 2
               risk factors represent important drivers for a patient developing ischemic heart disease, their significance
               in predicting post-CABG mortality risk appears likely confounded with presence of diabetes mellitus and
               poor renal function, which may also be sequela of obesity or diabetes.


               Although these risk models may be helpful to enhance the providers’ discussions with patients during
               the informed consent process or support provider discussions as to treatment-related risks for adverse
               events, the currently published CABG mortality risk models fall short of providing clinicians with
               useful information to optimize postoperative care consults, to ensure continuity of post-discharge care,
               or to enhance LT patients’ survival. While it would likely not be surprising to most clinicians that these
               modifiable risk factors are important considerations, the manner presented in LT risks models may give the
               impression that LT post-CABG mortality risk is set in stone at the time of surgery, rather than an evolving
               risk that can be mitigated or exacerbated at any time. Using follow-up time-period-based risks (e.g.,
               hemoglobin A1c management or continued tobacco use), therefore, future sequential modeling approaches
               may be needed to help better guide post-CABG follow-up care decisions and to optimize LT post-CABG
               survival.

               One risk factor that is potentially modifiable, but not in the traditional sense, is operative urgency or
               priority, meaning whether a given procedure was performed in the elective vs. urgent or even emergent
               manner with an unstable patient. As clinically relevant examples, it is important to know when to intervene
               in patients with active angina or acute myocardial infarction. While operating in a time sensitive manner
               under potentially suboptimal conditions may be unavoidable, the fact that priority or status variables have
               been identified so frequently as ST mortality risk factors would suggest that future research funding should
                                                                                 [16]
               be prioritized to evaluate the impact of differential pre-CABG waiting periods .

               A limited number of CABG mortality models found preoperative medications such as nitrates, anti-platelet
               agents, angiotensin converting enzyme inhibitor, or anti-arrhythmic medication were associated with
               mortality. Given risk assessment inconsistencies, some of these medications (e.g., nitrates) may have been
               markers for the severity of coronary disease or preoperative instability. Other medications may, in fact, be
                                                                                      [17]
               markers of optimal medical management during the pre- and postoperative periods .
   132   133   134   135   136   137   138   139   140   141   142